This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
AbbVie Beats on Q1 Earnings & Sales, Raises '25 EPS View
by Zacks Equity Research
ABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales performance of immunology drugs Rinvoq and Skyrizi.
RHHBYPositive Net Change JNJNegative Net Change ABBVNegative Net Change
biotechs earnings medical pharmaceuticals
CRISPR Therapeutics to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On CRSP's first-quarter 2025 earnings call, investors will likely focus on the sales numbers of its new gene therapy, Casgevy.
VRTXNegative Net Change BPMCNegative Net Change CTMXNegative Net Change CRSPNegative Net Change
biotechs
Can Moderna Keep the Beat Streak Alive This Earnings Season?
by Zacks Equity Research
When MRNA reports first-quarter earnings, investors will likely focus on pipeline updates.
MRKNegative Net Change MRNANegative Net Change CTMXNegative Net Change ARGXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter 2025 earnings release, given the absence of a marketed product.
NVAXNegative Net Change CTMXNegative Net Change ARGXPositive Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline
by Zacks Equity Research
Gilead Sciences' Q1 earnings and sales miss estimates on lower oncology drug sales. The stock is trading down.
GSKPositive Net Change GILDNegative Net Change ANIPNegative Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
CytomX Gears Up to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
On the Q1 2025 earnings call, investors can expect updates regarding the progress in the development of CTMX's lead candidate, CX-2051, for colorectal cancer.
AMGNNegative Net Change NVAXNegative Net Change CTMXNegative Net Change ARGXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Beam Therapeutics to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
In the absence of any marketed drugs, investors are set to focus on BEAM's pipeline updates when it reports first-quarter 2025 earnings.
NVAXNegative Net Change BEAMNegative Net Change CTMXNegative Net Change ARGXPositive Net Change
biotechs
Merck Q1 Earnings & Sales Beat Estimates, '25 EPS Outlook Cut
by Zacks Equity Research
MRK posts better-than-expected first-quarter results but trims its 2025 EPS outlook due to anticipated one-time charges.
AZNPositive Net Change MRKNegative Net Change ANIPNegative Net Change CTMXNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook
by Zacks Equity Research
BMY beats on both earnings and sales in the first quarter of 2025. The company raises its guidance for the full year.
BMYNegative Net Change PFENegative Net Change ANIPNegative Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?
by Ahan Chakraborty
Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips
by Zacks Equity Research
VKTX's first-quarter earnings miss estimates. The company remains on track to start the late-stage development of its obesity injection before June-end.
ANIPNegative Net Change VKTXNegative Net Change CTMXNegative Net Change ETNBPositive Net Change
biotechs earnings medical
Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More
by Ekta Bagri
BMY and REGN are in the spotlight this week following study data and regulatory updates, respectively.
REGNNegative Net Change SNYPositive Net Change BMYNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Amicus Therapeutics to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On FOLD's first-quarter 2025 earnings call, investors are likely to focus on the sales of lead drug Galafold and the combo drug, Pombiliti + Opfolda.
NVAXNegative Net Change FOLDNegative Net Change CTMXNegative Net Change ARGXPositive Net Change
biotechs
Implied Volatility Surging for BioMarin Stock Options
by Zacks Equity Research
Investors need to pay close attention to BMRN stock based on the movements in the options market lately.
BMRNNegative Net Change
biotechnology biotechs medical
Buy, Sell or Hold ABBV Stock? Key Tips Ahead of Q1 Earnings
by Sundeep Ganoria
Investors will likely focus on the sales performance of AbbVie's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports Q1 results later this week.
RHHBYPositive Net Change JNJNegative Net Change ABBVNegative Net Change
biotechs earnings-preview medical pharmaceuticals
Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know
by Zacks Equity Research
INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
NVSPositive Net Change INCYNegative Net Change CTMXNegative Net Change ARGXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Regeneron to Report Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports first-quarter results on April 29.
REGNNegative Net Change AZNPositive Net Change GILDNegative Net Change VRTXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Verastem Oncology to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of any marketed drugs, investors are set to focus on VSTM's pipeline updates when it reports first-quarter 2025 earnings.
NVAXNegative Net Change VSTMNegative Net Change CTMXNegative Net Change ARGXPositive Net Change
biotechs
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
by Ahan Chakraborty
Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.
SNYPositive Net Change BMYNegative Net Change MRKNegative Net Change GILDNegative Net Change ABBVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Cardiol Therapeutics Stock: Is Cannabis Potential Priced In?
by Sundeep Ganoria
Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors.
JAZZNegative Net Change KNSANegative Net Change CRDLNegative Net Change
biotechs marijuana medical pot-stocks
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study
by Zacks Equity Research
Eli Lilly's stock surges as its investigational oral GLP-1 pill, orforglipron, achieves the primary and key secondary goals in the first late-stage study for adults with T2D.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
by Sundeep Ganoria
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.
JAZZNegative Net Change HRMYNegative Net Change
biotechs cannabis marijuana marijuana-stocks medical pharmaceuticals
Viking Therapeutics to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors will focus on VKTX's pipeline updates when it reports first-quarter earnings.
NVAXNegative Net Change VKTXNegative Net Change CTMXNegative Net Change ARGXPositive Net Change
biotechs medical
Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?
by Ekta Bagri
Bristol Myers is looking to turn its business around, banking on the strong uptake of new drugs. However, the 2025 outlook is not bright and we recommend investors to wait and watch for now.
BMYNegative Net Change PFENegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?
by Ekta Bagri
Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be a significant boost. We recommend investors to wait and watch for now.
GSKPositive Net Change MRKNegative Net Change GILDNegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals